Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00832520
Recruitment Status : Terminated (Low accrual rate.)
First Posted : January 30, 2009
Results First Posted : December 18, 2012
Last Update Posted : April 10, 2018
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Prevention
Condition: Advanced Cancer
Intervention: Drug: Remeron (mirtazapine)

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment was low (13 of a target 59) which rendered planned statistical analyses impossible. The recruitment period spanned 07Apr2009 through 14Jul2010. All were recruited through the UNM Cancer Center medical clinic.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Remeron (Mirtazapine) Mirtazapine 15 mg orally at bed time for 8 weeks

Participant Flow:   Overall Study
    Remeron (Mirtazapine)

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Remeron (Mirtazapine) Mirtazapine 15 mg orally at bed time for 8 weeks

Baseline Measures
   Remeron (Mirtazapine) 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
Count of Participants
<=18 years      0   0.0% 
Between 18 and 65 years      8  61.5% 
>=65 years      5  38.5% 
[Units: Years]
Mean (Standard Deviation)
 59  (10) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      4  30.8% 
Male      9  69.2% 
Region of Enrollment 
[Units: Participants]
United States   13 

  Outcome Measures

1.  Primary:   Change in Weight   [ Time Frame: 8 weeks ]

2.  Secondary:   To Determine if the Quality of Life Improves After Starting Mirtazapine   [ Time Frame: 8 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Early termination leading to no subjects analyzed.There will be no publication, as this study was terminated after the original PI left employment with the institution.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Valerie Parks, RN
Organization: UNM Comprehensive Cancer Center
phone: 505-925-0390

Responsible Party: New Mexico Cancer Care Alliance Identifier: NCT00832520     History of Changes
Other Study ID Numbers: INST 0816
First Submitted: January 29, 2009
First Posted: January 30, 2009
Results First Submitted: July 20, 2012
Results First Posted: December 18, 2012
Last Update Posted: April 10, 2018